Andere talen Genome & Company

Aandelen

A314130

KR7314130006

slotkoers Korea S.E. Andere beurzen 00:00:00 10-05-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
7.180 ^KRW	0,00%		+4,82%	-42,51%

24/01	Genome & Company kondigt positieve resultaten aan van fase 2 klinisch onderzoek naar de combinatie van GEN-001 en Bavencio®? voor de behandeling van maagkanker Poster gepresenteerd op ASCO GI	CI
2023	Genome & Company kondigt positieve resultaten aan van tussentijdse analyse van Gen-001 Plus Avelumab (Bavencio®?) fase II studie	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Genome & Company Announces Positive Topline Results from Phase 2 Clinical Trial of Combination of GEN-001 and Bavencio®? for the Treatment of Gastric Cancer Poster Presented at ASCO GI	24/01
Genome & Company Announces Positive Results from Interim Analysis of Gen-001 Plus Avelumab (Bavencio®?) Phase II Trial	19-05-23
Genome & Company announced that it has received KRW 23 billion in funding from a group of investors	07-04-23
Genome & Company announced that it expects to receive KRW 23 billion in funding from a group of investors	05-04-23
Genome & Company announced that it has received KRW 34.34975035 billion in funding from a group of investors	02-09-22
Genome & Company announced that it expects to receive KRW 34.34975035 billion in funding from a group of investors	18-08-22
Genome and Company Announces Clinical Trial Collaboration with Merck & Co., Inc	04-03-22
Microbiome CDMO, List Labs, Partners with Genome And Company, to Create Global Microbiome Research, Development, and Manufacturing Powerhouse	21-09-21
Genome & Company(KOSDAQ:A314130) added to S&P Global BMI Index	20-09-21
Genome & Company agreed to acquire a 60% stake in List Biological Laboratories, Inc. for $27 million.	08-09-21
Genome and Company Signs Second Clinical Trial Collaboration and Supply Agreement (Phase 2) with Merck Kgaa, Darmstadt, Germany and Pfizer for Immuno-Oncology Microbiome Study	09-03-21
Genome & Company and Debiopharm Join Forces to Create New Highly Specific Therapies for Cancer Patients	25-02-21
Genome & Company Announces First Patient Dosed in Phase 1/1B Study of GEN-001	27-10-20
Genome & Company announced that it expects to receive KRW 19.99999001 billion in funding from Korea Development Bank, Investment Arm	26-08-20
Scioto Biosciences, Inc. announced that it has received $26.5 million in funding from Genome & Company and other investors	11-08-20
Scioto Biosciences, Inc. announced that it expects to receive $6.50074 million in funding	07-08-20
Genome & Company announced that it has received KRW 4.00002 billion in funding	25-06-20
Genome & Company announced that it expects to receive KRW 4.00002 billion in funding	17-06-20
Genome & Company announced that it has received KRW 3.62991 billion in funding	24-04-20
Genome & Company Receives FDA IND Clearance for GEN-001, its First Anti-Cancer Microbiome Therapeutic	20-04-20

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Genome & Company

Aandelen

A314130

KR7314130006

Andere talen

Filters